SRRA - Sierra Oncology, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.68
-0.57 (-4.30%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close13.25
Open13.21
Bid12.50 x 800
Ask12.84 x 1100
Day's Range12.16 - 13.21
52 Week Range0.22 - 14.25
Volume111,781
Avg. Volume2,252,214
Market Cap23.676M
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GuruFocus.com

    5 More Deep-Value Stocks for 2020

    More companies to consider for the new year that are trading at a discount to net-net working capital Continue reading...

  • Here is What Hedge Funds Think About Sierra Oncology, Inc. (SRRA)
    Insider Monkey

    Here is What Hedge Funds Think About Sierra Oncology, Inc. (SRRA)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • PR Newswire

    Sierra Oncology Announces Investor Event to Discuss Momelotinib Data Being Reported at ASH

    Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it will host an Analyst & Investor Event on Sunday, December 8th at 7:00 am ET to discuss newly reported clinical data for momelotinib that will be presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

  • PR Newswire

    Sierra Oncology Announces Closing of $103 Million Public Offering and Changes to its Board of Directors

    Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it has closed its previously announced underwritten public offering, with gross proceeds to Sierra Oncology of $103 million.

  • Do Institutions Own Shares In Sierra Oncology, Inc. (NASDAQ:SRRA)?
    Simply Wall St.

    Do Institutions Own Shares In Sierra Oncology, Inc. (NASDAQ:SRRA)?

    The big shareholder groups in Sierra Oncology, Inc. (NASDAQ:SRRA) have power over the company. Institutions will often...

  • Did Sierra Oncology, Inc. (NASDAQ:SRRA) Insiders Buy Up More Shares?
    Simply Wall St.

    Did Sierra Oncology, Inc. (NASDAQ:SRRA) Insiders Buy Up More Shares?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Hedge Funds Have Never Been More Bullish On Sierra Oncology, Inc. (SRRA)
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Sierra Oncology, Inc. (SRRA)

    You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros […]

  • Associated Press

    Sierra Oncology, Inc: 1Q Earnings Snapshot

    The Vancouver, British Columbia-based company said it had a loss of 17 cents per share. The company's shares closed at $1.49. A year ago, they were trading at $1.99. _____ This story was generated by Automated ...

  • Imagine Owning Sierra Oncology (NASDAQ:SRRA) And Trying To Stomach The 72% Share Price Drop
    Simply Wall St.

    Imagine Owning Sierra Oncology (NASDAQ:SRRA) And Trying To Stomach The 72% Share Price Drop

    Sierra Oncology, Inc. (NASDAQ:SRRA) shareholders should be happy to see the share price up 18% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. To wit, the share price sk...